Trial Profile
Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Recombinant Human Growth Hormone and/or Rosiglitazone in the Treatment of Human Immunodeficiency Virus-Associated Visceral Adiposity and Insulin Resistance
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Rosiglitazone (Primary) ; Somatropin (Primary)
- Indications HIV-associated lipodystrophy syndrome; Insulin resistance
- Focus Therapeutic Use
- 27 Apr 2016 New trial record
- 01 Mar 2016 Results of a substudy published in the HIV Clinical Trials.